author-photo

Giancarlo Bisagni

5

Papers

907

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

2019 Breast Care
Show All
- Source
- Cite
- Save
Citations (0)
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (29)
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (71)
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

2008 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (797)
Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma†

2002 Cancer
Show All
- Source
- Cite
- Save
Citations (10)